comorbidity with, 688
development and course of, 688
diagnostic criteria for, 686–687
diagnostic features of, 687
differential diagnosis of, 688
gender-related diagnostic issues in, 688
prevalence of, 687–688
risk and prognostic factors for, 688
specifiers for, 687
Withdrawal from substance, 481, 485–487
alcohol, 499–501
caffeine, 506–508
cannabis, 517–519
delirium due to, 598
development and course of, 487
duration of effects and, 486
laboratory findings associated with, 486–487
multiple substances, 486
opioids, 484, 547–549
other (or unknown) substance, 583–584
recording procedures for, 487
related to route of administration and speed of 
substance effects, 486
sedative, hypnotic, or anxiolytic, 484, 557–560
stimulant, 484, 569–570
tobacco, 484, 575–576
World Health Organization (WHO), 6, 23
International Classification of Diseases  (ICD), 21
revision process for ICD-11, 6, 10, 11–12
use of ICD-9-CM and ICD-10 codes, 12, 16, 
22, 23, 29
International Classification of Functioning, 
Disability and Health (ICF), 21, 734
World Health Organization Disability Assessment 
Schedule 2.0 (WHODAS), 16, 21, 734, 
745–748
additional scoring and interpretation guidance 
for DSM-5 users, 745–746